Quantitative Estimation of Hair Growth I. Androgenetic Alopecia in Women: Effect of Minoxidil

Price, Vera H.; Menefee, Emory

doi:10.1111/1523-1747.ep12514348

Cited by 88 publications

(58 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This increase in hair coverage is due to an increase in hair thickness as shown by histological examination [14], the direct measurement of hair thickness [17] and by the continuous increase in hair weight [18]. Although the Ludwig pattern of AGA in women differs in appearance from the Hamilton pattern occurring in men, these pathophysiological mechanisms seem to be similar, because female AGA patients treated with cyproterone acetate [19] or minoxidil [20, 21] experience an increase in hair thickness or hair weight. Therefore, a reliable hair-counting method should primarily be able to calculate the number and thickness of hairs, which is stable within at least 1 cm above the scalp [22, 23], in a defined area of the scalp.…”

Section: Discussionmentioning

confidence: 99%

Trichoscan: What Is New?

Hoffmann

2005

Dermatology

View full text Add to dashboard Cite

The treatment of androgenetic alopecia (AGA) is usually long lasting, and the effects of treatment attempts are difficult to measure. Consequently, there was a need for a sensitive tool to monitor hair loss and treatment response. Therefore, we developed the Trichoscan as a method which combines epiluminescence microscopy with automatic digital image analysis for the measurement of human hair. The Trichoscan is able to analyze all important parameters of hair growth (density, diameter, growth rate, vellus and terminal hair density) with an intraclass correlation of approximately 91% within the same Trichoscan operator and an intraclass correlation of approximately 97% for different Trichoscan operators. The application of the technique was demonstrated by comparison of the hair parameters in 9 men with frontal balding which were treated for 6 months with 5% minoxidil. Even in this small cohort of patients, we noticed after 3 months of treatment compared to baseline a significant increase in hair density (+21.3 hairs/cm²; p = 0.047) and cumulative hair thickness (+0.61 mm; p = 0.008) and after 6 months a significant increase in hair density (+34 hairs/cm²; p = 0.011) and cumulative hair thickness (+0.88 mm; p = 0.010). The study shows that the Trichoscan has many advantages. It can be used for clinical studies to compare placebo versus treatment or to compare the relative potencies of different hair-growth-promoting substances. It can be used for studying AGA or other forms of diffuse hair loss, and it can be adopted to study the effect of drugs or laser treatment on hypertrichosis or hirsutism. The drawbacks, however, are that the Trichoscan still needs a hair dye for contrast enhancement and the measurement area must be clipped before analysis. This mini-review summarizes recent attempts to optimize the technique and shows new options such as the calculation of follicular units or the ‘anagen hair count’.

show abstract

Section: Discussionmentioning

confidence: 99%

Trichoscan: What Is New?

Hoffmann

2005

Dermatology

View full text Add to dashboard Cite

show abstract

“…It could also be used to estimate hair growth rate. Reliable and quantitative measurement of hair growth rate is essential for assessing treatments intended to increase hair growth (Barth, 1986: Price & Menefee, 1990.…”

Section: Discussionmentioning

confidence: 99%

The measurement of a new antimicrobial quinolone in hair as an index of drug exposure.

Nakano

Akiyama

Nakashima

1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. Scalp hair samples were obtained at 1 month intervals up to 5 months from healthy male volunteers participating in a phase I study of a new antimicrobial quinolone, OPC‐17116. 2. Hair was sectioned into 1 cm lengths from the scalp end. Corresponding portions from five pieces of hair were dissolved in 1 N NaOH and assayed for OPC‐17116 by h.p.l.c. 3. In all subjects taking a single dose (400 mg, n = 5) or repeated doses (400 mg day‐1, twice daily, for 6.5 days, n = 6), the drug was detected in the portions of hair corresponding to the administration period, assuming a hair growth rate of 1 cm/month. 4. OPC‐17116 (300 mg day‐1, three times daily, for 2 days) was given to four healthy male volunteers, from whom hair samples were obtained at 1 month and 3 months. The drug was detected in 1 to 4 consecutive 2.5‐mm long portions of a single hair and there was no significant axial diffusion of the agent along the hair shaft with time. 5. These findings indicate the utility of measuring this quinolone derivative in hair as an index of exposure, and as a time‐marker for the hair analysis of other drugs.

show abstract

“…A magnetic resonance imaging or computed tomography of the brain demonstrating brain metastases was required. A baseline hair score on the scalp was performed in each patient (11)(12)(13)(14). Patients were to be seen weekly during radiation, 1 to 2 weeks after the completion of radiation, and at 4 weeks and 6 weeks after the completion of radiation.…”

Section: Methodsmentioning

confidence: 99%

“…This distance sometimes varied among patients based on the ability to count hairs. Hair counts of nonvellus hair were obtained from these photographs as described previously (11)(12)(13)(14). Several end points were followed as described below.…”

Section: Methodsmentioning

confidence: 99%

A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy

Metz

Smith

Lustig

et al. 2004

Clinical Cancer Research

135

View full text Add to dashboard Cite

Purpose: Complete alopecia is a universal complication of whole brain radiation therapy which contributes to patient anxiety over treatment. Tempol, a nitroxide radioprotector, has been shown to protect against radiation-induced alopecia in an animal model. This phase Ib study was designed to evaluate the safety and side effect profile of topical Tempol in patients with brain metastases being treated with whole brain radiotherapy.Experimental Design: Twelve patients with metastatic cancer to the brain were enrolled in the study between October 2000 and February 2003. Tempol (70 mg/ml concentration solution) was applied topically to the scalp 15 minutes before and washed off immediately after the completion of each of 10 fractions of whole brain radiation. Pharmacokinetic studies to evaluate the systemic absorption of Tempol were performed. Patients were assessed for toxicity before, during, and after Tempol administration. A secondary end point of the study, hair retention, was also scored.Results: Eleven patients were treated with topical Tempol. Adverse events that were considered possibly, probably, or definitely related to Tempol, included asymptomatic grade 2 (two patients) and grade 1 (one patient) hypoglycemia, grade 1 forehead skin redness (one patient), grade 1 dry scalp (one patient), and grade 1 tingling sensation on the scalp (one patient). Tempol was not detected in blood samples from more than 50% of the patients. Mean maximum Tempol levels for individual patients at any time point varied from 0.4 to 3.1 mol/L. Hair retention was localized to the base of the scalp where the Tempol solution pooled after application in the first four patients on the study. Subsequently, full scalp hair retention was seen in three of final five evaluable patients after gauze had been wrapped around the head to hold the solution against the scalp.Conclusions: This study demonstrates that topical application of Tempol to the scalp before whole brain radiation is safe and well tolerated. Evidence of protection against radiation-induced alopecia was observed. A phase II study that uses a gel formulation to increase the exposure of scalp to Tempol has been initiated.

show abstract

Quantitative Estimation of Hair Growth I. Androgenetic Alopecia in Women: Effect of Minoxidil

Cited by 88 publications

References 9 publications

Trichoscan: What Is New?

Trichoscan: What Is New?

The measurement of a new antimicrobial quinolone in hair as an index of drug exposure.

A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy

Contact Info

Product

Resources

About